ArticleObstetrics and gynecology2017
Cost of Care for the Initial Management of Ovarian Cancer.
Article in Obstetrics and gynecology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2021Pooled it
- The potential for opportunistic salpingectomy to reduce ovarian cancer in women undergoing non-gynecologic surgery.Gynecologic oncology reports · 2025Article
- Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance.International journal of molecular sciences · 2025Review
- Cost of ovarian cancer by the phase of care in the United States.American journal of obstetrics and gynecology · 2025Article
- Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer.Gynecologic oncology reports · 2025Review
- Beyond Sterilization: A Comprehensive Review on the Safety and Efficacy of Opportunistic Salpingectomy as a Preventative Strategy for Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Intermittent fasting induced ketogenesis inhibits mouse epithelial ovarian cancer by promoting antitumor T cell response.iScience · 2023Article
- Pattern of Care in Real-World Scenario on Advanced Epithelial Ovarian Cancer in a Tertiary Referral Oncology Centre in India - ISPSM Collaborative Study.Indian journal of surgical oncology · 2023Article
- Impact of robotic surgery on patient flow and resource use intensity in ovarian cancer.Journal of robotic surgery · 2023Article
- Health services costs for ovarian cancer in Australia: Estimates from the 45 and Up Study.PloS one · 2023Article
- Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022Article
- Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.JCO clinical cancer informatics · 2022Article
- Nanomaterial-based biosensor developing as a route toward in vitro diagnosis of early ovarian cancer.Materials today. Bio · 2022Article
- Employment disruption among women with gynecologic cancers.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022Article
- Hormonally Active Contraceptives, Part II: Sociological, Environmental, and Economic Impact.The Linacre quarterly · 2021Article
- Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.American journal of obstetrics and gynecology · 2021Article
- Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.Gynecologic oncology · 2021Article
- Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer.American journal of obstetrics and gynecology · 2020Article
- Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis.Journal of managed care & specialty pharmacy · 2020Article
- Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo examine the cost of care during the first year after a diagnosis of ovarian cancer, estimate the sources of cost, and explore the out-of-pocket costs.
methodsWe performed a retrospective cohort study of women with ovarian cancer diagnosed from 2009 to 2012 who underwent both surgery and adjuvant chemotherapy using the Truven Health MarketScan database. This database is comprised of patients covered by commercial insurance sponsored by more than 100 employers in the United States. Medical expenditures, including physician reimbursement, for a 12-month period beginning on the date of surgery were estimated. All payments were examined, including out-of-pocket costs for patients. Payments were divided into expenditures for inpatient care, outpatient care (including chemotherapy), and outpatient drug costs. The 12-month treatment period was divided into three phases: surgery to 30 days (operative period), 1-6 months (adjuvant therapy), and 6-12 months after surgery. The primary outcome was the overall cost of care within the first year of diagnosis of ovarian cancer; secondary outcomes included assessment of factors associated with cost.
resultsA total of 26,548 women with ovarian cancer who underwent surgery were identified. After exclusion of patients with incomplete insurance enrollment or coverage, those who did not undergo chemotherapy, and those with capitated plans, our cohort consisted of 5,031 women. The median total medical expenditures per patient during the first year after the index procedure were $93,632 (interquartile range $62,319-140,140). Inpatient services accounted for $30,708 (interquartile range $20,102-51,107; 37.8%) in expenditures, outpatient services $52,700 (interquartile range $31,210-83,206; 58.3%), and outpatient drug costs $1,814 (interquartile range $603-4,402; 3.8%). The median out-of-pocket expense was $2,988 (interquartile range $1,649-5,088). This included $1,509 (interquartile range $705-2,878) for outpatient services, $589 (interquartile range $3-1,715) for inpatient services, and $351 (interquartile range $149-656) for outpatient drug costs.
conclusionThe average cost of care for women with ovarian cancer in the first year after surgery is approximately $100,000. Patients bear approximately 3% of these costs in the form of out-of-pocket expenses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.